Annual Cash & Cash Equivalents
$340.45 M
-$127.28 M-27.21%
December 31, 2023
Summary
- As of February 7, 2025, NAMS annual cash & cash equivalents is $340.45 million, with the most recent change of -$127.28 million (-27.21%) on December 31, 2023.
- During the last 3 years, NAMS annual cash & cash equivalents has risen by +$330.78 million (+3421.16%).
- NAMS annual cash & cash equivalents is now -27.21% below its all-time high of $467.73 million, reached on December 31, 2022.
Performance
NAMS Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$422.73 M
-$7.98 M-1.85%
September 30, 2024
Summary
- As of February 7, 2025, NAMS quarterly cash and cash equivalents is $422.73 million, with the most recent change of -$7.98 million (-1.85%) on September 30, 2024.
- NAMS quarterly cash and cash equivalents is now -12.14% below its all-time high of $481.15 million, reached on March 31, 2024.
Performance
NAMS Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
NAMS Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -27.2% | - |
| 3 y3 years | +3421.2% | -9.6% |
| 5 y5 years | +3421.2% | -9.6% |
NAMS Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -27.2% | +466.4% | -12.1% | +603.2% |
| 5 y | 5-year | -27.2% | +3421.2% | -12.1% | +603.2% |
| alltime | all time | -27.2% | +3421.2% | -12.1% | +603.2% |
NewAmsterdam Pharma Company NV Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $422.73 M(-1.9%) |
| Jun 2024 | - | $430.71 M(-10.5%) |
| Mar 2024 | - | $481.15 M(+41.3%) |
| Dec 2023 | $340.45 M | $340.45 M(-18.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2023 | - | $416.76 M(-10.9%) |
| Dec 2022 | $467.73 M(+678.1%) | $467.73 M(+400.4%) |
| Jun 2022 | - | $93.47 M(+55.5%) |
| Dec 2021 | $60.11 M(+521.7%) | $60.11 M |
| Dec 2020 | $9.67 M | - |
FAQ
- What is NewAmsterdam Pharma Company NV annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for NewAmsterdam Pharma Company NV?
- What is NewAmsterdam Pharma Company NV annual cash & cash equivalents year-on-year change?
- What is NewAmsterdam Pharma Company NV quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for NewAmsterdam Pharma Company NV?
What is NewAmsterdam Pharma Company NV annual cash & cash equivalents?
The current annual cash & cash equivalents of NAMS is $340.45 M
What is the all time high annual cash & cash equivalents for NewAmsterdam Pharma Company NV?
NewAmsterdam Pharma Company NV all-time high annual cash & cash equivalents is $467.73 M
What is NewAmsterdam Pharma Company NV annual cash & cash equivalents year-on-year change?
Over the past year, NAMS annual cash & cash equivalents has changed by -$127.28 M (-27.21%)
What is NewAmsterdam Pharma Company NV quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of NAMS is $422.73 M
What is the all time high quarterly cash and cash equivalents for NewAmsterdam Pharma Company NV?
NewAmsterdam Pharma Company NV all-time high quarterly cash and cash equivalents is $481.15 M